🇺🇸 Dilaudid (hydromorphone) in United States

257 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Pain — 64 reports (24.9%)
  2. Nausea — 37 reports (14.4%)
  3. Fatigue — 24 reports (9.34%)
  4. Drug Withdrawal Syndrome — 21 reports (8.17%)
  5. Pneumonia — 21 reports (8.17%)
  6. Overdose — 20 reports (7.78%)
  7. Vomiting — 20 reports (7.78%)
  8. Diarrhoea — 17 reports (6.61%)
  9. Muscle Spasms — 17 reports (6.61%)
  10. Headache — 16 reports (6.23%)

Source database →

Other Pain Management approved in United States

Frequently asked questions

Is Dilaudid (hydromorphone) approved in United States?

Dilaudid (hydromorphone) does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Dilaudid (hydromorphone) in United States?

University of Nebraska is the originator. The local marketing authorisation holder may differ — check the official source linked above.